This indicates that the majority of the immunoproteasome catalytic activity comes from LMP2 and LMP7, defining their importance for IFNγ-mediated resistance to venetoclax, and as such, as potential targets in the treatment of CLL. This evidence concerns the gene PSMB9 and B-cell chronic lymphocytic leukemia.